Wide Ranks

KRRO

Korro Bio, Inc.

54.99

Top Statistics
Market Cap 515 M Forward PE -5.65 Revenue Growth 0.00 %
Current Ratio 11.23 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -4.51 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 136 M Total Cash Per Share 14.70 Total Debt 41 M
Total Debt To Equity 23.26 Current Ratio 11.23 Book Value Per Share 19.28
All Measures
Short Ratio 121.00 % Message Board Id finmb_619256344 Shares Short Prior Month 274235
Return On Equity -0.7451 City Cambridge Uuid 2796a462-87ad-3357-959a-ace1e7e2b1d2
Previous Close 53.25 First Trade Date Epoch Utc 1 B Book Value 19.28
Total Debt 41 M Volume 35294 Price To Book 2.85
Last Split Date 1 B Fifty Two Week Low 30.00 Total Cash Per Share 14.70
Shares Short Previous Month Date 1 B Target Median Price 130.00 Max Age 86400
Recommendation Mean 1.57 Sand P52 Week Change 0.3133 Target Mean Price 137.76
Net Income To Common -87808000 Short Percent Of Float 0.0344 Implied Shares Outstanding 9 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 90960
Average Volume10days 90960 Total Cash 136 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0644 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 53.25 Target Low Price 105.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 51.80 Open 53.17
Free Cashflow -81129872 State MA Dividend Yield 0.00 %
Return On Assets -0.3527 Time Zone Short Name EST Trailing Eps -9.43
Day Low 50.92 Address1 One Kendall Square Shares Outstanding 9 M
Price Hint 2 Target High Price 180.00 Website https://www.korrobio.com
52 Week Change 0.3121 Average Volume 119332 Forward Eps -10.10
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 1080.10 %
Last Split Factor 1:50 Regular Market Day High 55.20 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 23.26 Fifty Two Week High 98.00
Day High 55.20 Shares Short 244854 Regular Market Open 53.17
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0261 Operating Cashflow -73686000 Currency USD
Time Zone Full Name America/New_York Market Cap 515 M Is_nasdaq_100 False
Zip 02139 Quote Type EQUITY Industry Biotechnology
Long Name Korro Bio, Inc. Regular Market Day Low 50.92 Held Percent Institutions 0.9137
Current Price 54.99 Address2 Building 600-700 Suite 6-401 Enterprise To Ebitda -4.51
Financial Currency USD Current Ratio 11.23 Industry Disp Biotechnology
Number Of Analyst Opinions 7 Country United States Float Shares 4 M
Two Hundred Day Average 51.48 Enterprise Value 417 M Forward PE -5.65
Regular Market Volume 35294 Ebitda -92466000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States.

Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates.

The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain.

Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases.

Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.